title: Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study.
abstract: OBJECTIVE
  Recently, Sofosbuvir was launched in India at affordable cost. We conducted a real-life study to determine the efficacy and safety of Sofosbuvir plus Ribavirin, with and without peginterferon-alfa 2a, in patients with chronic hepatitis C (CHC) genotype 3, the commonest genotype in South Asia.
  
  
  METHODS
  This study included data of CHC patients from 11 sites in northern India between March 2015 and December 2015 (n = 1203). Patients with CHC genotype 3 (n = 931), who were treated with either Sofosbuvir 400 mg plus weight-based Ribavirin, daily ×24 weeks (n = 432) (dual therapy), or Peginterferon-α2a 180 mcg weekly, Sofosbuvir 400 mg plus weight-based Ribavirin, daily ×12 weeks (n = 499) (triple therapy) were included for analysis. Primary outcome was the proportion of patients achieving sustained viral response at 12 weeks post-therapy.
  
  
  RESULTS
  The overall SVR rates were 91 and 92% in the dual and triple therapy arms, respectively. The SVR rates in treatment experienced were 67 and 74% versus 93 and 96% in naïve patients, on the dual and triple therapy arms, respectively. The SVR rates of cirrhotics were 73 and 75% on the dual and triple treatment arms, respectively. The SVR rates were low in the experienced cirrhotic patients: 44% (dual therapy) and 58% (triple therapy). Common adverse events were fatigue, headache, and myalgia.
  
  
  CONCLUSIONS
  Both dual and triple therapy regimes resulted in SVR rates of >95% in CHC genotype 3 who were naive non-cirrhotics. However, the SVR rates were low in treatment-experienced cirrhotics.
authors.affiliation: Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India. sandeepsidhu1963@gmail.com.
authors.forename: Sandeep Singh
authors.initials: SS
authors.lastname: Sidhu
authors.affiliation: Department of Gastroenterology, SatguruPartap Singh Hospital, Ludhiana, Punjab, India.
authors.forename: Nirmaljeet Singh
authors.initials: NS
authors.lastname: Malhi
authors.affiliation: Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.
authors.forename: Omesh
authors.initials: O
authors.lastname: Goyal
authors.affiliation: Department of Gastroenterology, Malwa Hospital, Bathinda, Punjab, India.
authors.forename: Rupinder
authors.initials: R
authors.lastname: Singh
authors.affiliation: Department of Gastroenterology, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh Union Territory, India.
authors.forename: Usha
authors.initials: U
authors.lastname: Dutta
authors.affiliation: Department of Gastroenterology, AIMC Bassi Hospital, Ludhiana, Punjab, India.
authors.forename: Rajiv
authors.initials: R
authors.lastname: Grover
authors.affiliation: Department of Gastroenterology, Parvati Hospital, Amritsar, Punjab, India.
authors.forename: J S
authors.initials: JS
authors.lastname: Sidhu
authors.affiliation: Department of Gastroenterology, Premier Gastroenterology Institute, Jalandhar, Punjab, India.
authors.forename: Vijay
authors.initials: V
authors.lastname: Nanda
authors.affiliation: Department of Gastroenterology, Deep Hospital, Ludhiana, Punjab, India.
authors.forename: Harmeet
authors.initials: H
authors.lastname: Saluja
authors.affiliation: Department of Gastroenterology, Max SuperspecialityHospital, Bathinda, Punjab, India.
authors.forename: Ajesh
authors.initials: A
authors.lastname: Bansal
authors.affiliation: Department of Gastroenterology, Care Hospital, Bathinda, Punjab, India.
authors.forename: Gursewak
authors.initials: G
authors.lastname: Singh
authors.affiliation: Himalayan Institute of Medical Sciences, Dehradun, UttarKhand, India.
authors.forename: Alok
authors.initials: A
authors.lastname: Sehgal
authors.affiliation: Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.
authors.forename: Harsh
authors.initials: H
authors.lastname: Kishore
authors.affiliation: Himalayan Institute of Medical Sciences, Dehradun, UttarKhand, India.
authors.forename: Simran
authors.initials: S
authors.lastname: Sidhu
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D001208:Asia / Q000453:epidemiology; D004359:Drug Therapy, Combination / Q000379:methods* / Q000639:trends; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D007194:India / Q000453:epidemiology; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D012328:RNA Viruses / Q000187:drug effects; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D012189:Retrospective Studies; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000069474:Sofosbuvir / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000072230:Sustained Virologic Response; D016896:Treatment Outcome; D019562:Viral Load / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a; D000069474:Sofosbuvir
keywords: Chronic hepatitis C; Pegylated interferon; Sofosbuvir and Ribavirin